Neratinib

Overview

Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC 50 s of 59 nM and 92 nM, respectively.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-32721
• CAS No.: 698387-09-6
• Molecular Formula: C30H29ClN6O3
• Molecular Weight: 557.04
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.83 mg/mL (1.49 mM); Clear solution
• Availability: In-stock

Source

Original product source